Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Recruiting · NCT02009345 · Observational (researchers observe without assigning treatment) · Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
View the official record on ClinicalTrials.gov →What this trial is about
Familial hypercholesterolemia (FH) is the most frequent genetic lipoprotein disorder associated with premature CAD. In Canada, the burden of disease is estimated to be approximately 83,500 patients. The goal of this initiative is to create a registry of subjects with FH across Canada. Rare diseases of lipoprotein metabolism are also included. Using a "hub and spoke" model, the registry extends in various communities to link primary care physicians with provincial academic centers. The registry includes clinical, biochemical and demographic information. Specimens (plasma/serum and DNA) are collected for biobanking. The "local" portion of the registry is available for clinicians to manage patient care, and identify relatives for screening and treatment (cascade screening). The Canada-wide registry, which is completely anonymized, will be made available to provide advice to general practitioners and to support collaborative studies in biomedical, clinical, health outcomes and health economics research. The data extracted for the provincial portion of the database will allow administrative database research that will provide important information to key stakeholders and permit allocation of resources. It will also allow a sound and uniform rationale for the use of novel therapeutic agents and provide expert advice to regulatory agencies. At the Canadian level, the database will allow clinicians and researchers to determine the burden of disease and the long-term effects of treatment. Through the creation of a Canada-wide network of academic clinics, integrating lipid specialists, endocrinologists and cardiologists, the Canadian FH registry will lead to significant benefits for FH patients, clinicians and researchers, biopharmaceutical industry and government.
Who can take part
Inclusion criteria
- Clinical diagnostic criteria for FH, which are:
- Family and/or personal history of high cholesterol
- Family and/or personal history of heart disease
- Abnormal growth on tendons, accumulation of fatty material in the eye
- Family history of FH
- Severe disorder of cholesterol and other lipids in the blood
Exclusion criteria
- No exclusion criterion
Where it is running
1 location listed.
- Research Institute of the McGill University Health Centre: Glen site - Montreal, Quebec, Canada